Scotia Capital Inc. Imv Inc. Transaction History

Scotia Capital Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.47 - $0.75 $564 - $900	1,200 Added 7.54%	17,110 $9,000
Q2 2022 Aug 05, 2022	BUY	$0.56 - $1.45 $172 - $446	308 Added 1.97%	15,910 $10,000
Q1 2022 May 09, 2022	SELL	$1.07 - $1.5 $329 - $462	-308 Reduced 1.94%	15,602 $22,000
Q4 2021 Feb 11, 2022	SELL	$1.22 - $1.78 $22,174 - $32,353	-18,176 Reduced 53.32%	15,910 $19,000
Q3 2021 Nov 12, 2021	BUY	$1.35 - $2.16 $5,440 - $8,704	4,030 Added 13.41%	34,086 $57,000
Q2 2021 Aug 12, 2021	SELL	$2.12 - $3.24 $16,296 - $24,905	-7,687 Reduced 20.37%	30,056 $64,000
Q1 2021 May 06, 2021	SELL	$2.92 - $4.41 $29,611 - $44,721	-10,141 Reduced 21.18%	37,743 $120,000
Q4 2020 Feb 11, 2021	BUY	$2.9 - $4.4 $26,520 - $40,238	9,145 Added 23.61%	47,884 $147,000
Q3 2020 Nov 12, 2020	BUY	$2.87 - $5.95 $25,187 - $52,217	8,776 Added 29.29%	38,739 $172,000
Q2 2020 Aug 11, 2020	BUY	$1.52 - $3.63 $25,397 - $60,653	16,709 Added 126.07%	29,963 $94,000
Q1 2020 May 15, 2020	BUY	$1.4 - $4.92 $18,555 - $65,209	13,254 New	13,254 $22,000
Q4 2019 Feb 13, 2020	SELL	$2.15 - $3.1 $34,799 - $50,176	-16,186 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.25 - $3.82 $36,418 - $61,830	16,186 New	16,186 $39,000

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of Scotia Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Scotia Capital Inc. with notifications on news.